Your session is about to expire
← Back to Search
Unknown
A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants
Phase 1
Waitlist Available
Research Sponsored by Gasherbrum Bio, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial is testing a new capsule called GSBR-1290 to see if it is safe and well-tolerated when taken by mouth. The study involves healthy adult participants from both Japanese and non-Japanese backgrounds. Researchers will give different doses over a period of time to compare the effects between these groups.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
2Treatment groups
Experimental Treatment
Group I: Cohort 2: GSBR-1290Experimental Treatment1 Intervention
Healthy non-Japanese participants (Caucasians or African Americans) will receive once daily doses of study drug (GSBR-1290 oral capsules) for up to 4 weeks.
Group II: Cohort 1: GSBR-1290 or PlaceboExperimental Treatment2 Interventions
Healthy Japanese participants will receive once daily doses of study drug (GSBR-1290 or placebo oral capsules) for up to 4 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GSBR-1290
2023
Completed Phase 2
~160
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Gasherbrum Bio, IncLead Sponsor
2 Previous Clinical Trials
212 Total Patients Enrolled
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsLead Sponsor
4 Previous Clinical Trials
514 Total Patients Enrolled